1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-12.88%
Cash & equivalents declining -12.88% while Drug Manufacturers - Specialty & Generic shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
26.04%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-7.82%
Receivables growth is below half the Drug Manufacturers - Specialty & Generic median of 1.00% (much lower). Joel Greenblatt would investigate if this reflects stronger collection discipline.
-5.96%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
24.51%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
23.90%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 2.19%. Joel Greenblatt sees a potential liquidity edge if well allocated.
133.97%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
1.85%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-63.59%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-52.27%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
292.14%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
No Data
No Data available this quarter, please select a different quarter.
-50.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
131.33%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.93%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
48.98%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 1.60%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
48.70%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
120.14%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
0.00%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
No Data
No Data available this quarter, please select a different quarter.
62.31%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 2.71%. Jim Chanos suspects potential working capital strain.
7.50%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.50%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
27.47%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.27%. Jim Chanos suspects an alarming rise in overall leverage.
44.83%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
75.95%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
36.16%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
50.78%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 2.87%. Joel Greenblatt sees stronger equity growth vs. peers.
48.98%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 1.60%. Joel Greenblatt sees more aggressive expansions than peers.
794.95%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
18.59%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
15.49%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.24%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
